FIG 5.
PFS in patients (A) with or (B) without baseline liver metastases and OS in patients (C) with or (D) without baseline liver metastases. Patients were followed for a minimum of 77 months. aDescriptive analysis. HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival.